Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.42 |
| ▸ | AXL | P30530 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 10/20 | 0.39 |
| ▸ | HTR1B | P28222 | 10/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR1F | P30939 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3147519 | 0.80 | HTR6 (0.60) | HTR6 | |
| SCHEMBL13947345 | 0.77 | HTR6 (0.69) | HTR6HTR1DHTR1BHTR1A | |
| SCHEMBL3320144 | 0.76 | HTR6 (0.53) | HTR6HTR1A | |
| SCHEMBL3323052 | 0.76 | HTR6 (0.69) | HTR6 | |
| SCHEMBL3143108 | 0.74 | HTR6 (0.56) | HTR6 | |
| SCHEMBL8149484 | 0.72 | TP53 (0.48) | HTR1DHTR1BHTR1AHTR1F | |
| SCHEMBL18993225 | 0.72 | ITK (0.46) | HTR6AXLMAPK1HTR1DHTR1B | |
| SCHEMBL5906326 | 0.71 | TLR9 (0.35) | — | |
| SCHEMBL3323083 | 0.71 | HTR6 (0.72) | HTR6HTR1DHTR1BHTR1AHTR1F | |
| SCHEMBL27708765 | 0.71 | HTR6 (0.41) | HTR6AXLHTR1DHTR1BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1841427-A2 | COMPOSITIONS AND THERAPEUTIC METHODS UTILIZING A COMBINATION OF A 5-HT1F INHIBITOR AND AN NSAID | Pozen, Inc. (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20060178349-A1 | Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID | POZEN INC. (US) | 2006-08-10 | — | — | US | disclosed |
| WO-2006081127-A2 | COMPOSITIONS AND THERAPEUTIC METHODS UTILIZING A COMBINATION OF A 5-HT1F INHIBITOR AND AN NSAID | POZEN INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| EP-0978514-B1 | Indazole derivatives as 5-HT1F agonists | LILLY CO ELI (US) | 2004-12-15 | — | — | EP | disclosed |
| US-6133290-A | 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| WO-2000006173-A1 | 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0978514-A1 | Indazole derivatives as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2000-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178349-A1 | Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID | HTR1F, HTR1A, HTR1E | HTR6 14/4885AXL 3835/4885MAPK1 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.